Association between heroin dependence and prodynorphin gene polymorphisms

Brain Research Bulletin

Volumn 85, Issue 3-4, 2011, Pages 238-242

  Wei, S G ^a,b   Zhu, Y S ^a,c   Lai, J H ^a,b   Xue, H X ^a,b   Chai, Z Q ^a   Li, S B ^a,b  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c Key Laboratory of Reproduction and Genetics of Ningxia Hui Autonomous Region   (China)

Author keywords

3'Untranslated region; Heroin addiction; Polymorphism; Prodynorphin; Promoter

Indexed keywords

PRODYNORPHIN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; CHI-SQUARE DISTRIBUTION; ENKEPHALINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEROIN DEPENDENCE; HUMANS; MALE; MINISATELLITE REPEATS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PRECURSORS;

EID: 79957861034     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.02.010     Document Type: Article

References (39)

1. Brandon C.L., Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur. J. Neurosci. 2003, 18:1584-1592.
2. Cadoret R.J., Yates W.R., Troughton E., Woodworth G., Stewart M.A. Adoption study demonstrating two genetic pathways to drug abuse. Arch. Gen. Psychiatry 1995, 52:42-52.
3. Chen A.C., LaForge K.S., Ho A., McHugh P.F., Kellogg S., Bell K., Schluger R.P., Leal S.M., Kreek M.J. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am. J. Med. Genet. 2002, 114:429-435.
4. Chen J.M., Ferec C., Cooper D.N. A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants. Hum. Genet. 2006, 120:301-333.
5. Clarke T.K., Krause K., Li T., Schumann G. An association of prodynorphin polymorphisms and opioid dependence in females in a Chinese population. Addict. Biol. 2009, 14:366-370.
6. Dahl J.P., Weller A.E., Kampman K.M., Oslin D.W., Lohoff F.W., Ferraro T.N., O'Brien C.P., Berrettini W.H. Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2005, 139B:106-108.
7. Drolet G., Dumont E.C., Gosselin I., Kinkead R., Laforest S., Trottier J.F. Role of endogenous opioid system in the regulation of the stress response. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:729-741.
8. Frankel P.S., Alburges M.E., Bush L., Hanson G.R., Kish S.J. Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 2008, 55:41-46.
9. Galeote L., Berrendero F., Bura S.A., Zimmer A., Maldonado R. Prodynorphin gene disruption increases the sensitivity to nicotine self-administration in mice. Int. J. Neuropsychopharmacol. 2009, 12:615-625.
10. Galeote L., Maldonado R., Berrendero F. Involvement of kappa/dynorphin system in the development of tolerance to nicotine-induced antinociception. J. Neurochem. 2008, 105:1358-1368.
11. Glick S.D., Maisonneuve I.M., Raucci J., Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 1995, 681:147-152.
12. Goldman D., Oroszi G., Ducci F. The genetics of addictions: uncovering the genes. Nat. Rev. Genet. 2005, 6:521-532.
13. Hauser K.F., Aldrich J.V., Anderson K.J., Bakalkin G., Christie M.J., Hall E.D., Knapp P.E., Scheff S.W., Singh I.N., Vissel B., Woods A.S., Yakovleva T., Shippenberg T.S. Pathobiology of dynorphins in trauma and disease. Front. Biosci. 2005, 10:216-235.
14. Horikawa S., Takai T., Toyosato M., Takahashi H., Noda M., Kakidani H., Kubo T., Hirose T., Inayama S., Hayashida H., et al. Isolation and structural organization of the human preproenkephalin B gene. Nature 1983, 306:611-614.
15. Hurd Y.L., Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 1993, 13:357-369.
16. Kelley A.E., Bakshi V.P., Haber S.N., Steininger T.L., Will M.J., Zhang M. Opioid modulation of taste hedonics within the ventral striatum. Physiol. Behav. 2002, 76:365-377.
17. Kendler K.S., Jacobson K.C., Prescott C.A., Neale M.C. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am. J. Psychiatry 2003, 160:687-695.
18. Koob G., Kreek M.J. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am. J. Psychiatry 2007, 164:1149-1159.
19. Kreek M.J., LaForge K.S., Butelman E. Pharmacotherapy of addictions. Nat. Rev. Drug Discov. 2002, 1:710-726.
20. Mathieu-Kia A.M., Besson M.J. Repeated administration of cocaine, nicotine and ethanol: effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat. Brain Res. Mol. Brain Res. 1998, 54:141-151.
21. Messersmith D.J., Kim D.J., Iadarola M.J. Transcription factor regulation of prodynorphin gene expression following rat hindpaw inflammation. Brain Res. Mol. Brain Res. 1998, 53:260-269.
22. Mignone F., Gissi C., Liuni S., Pesole G. Untranslated regions of mRNAs. Genome Biol. 2002, 3. REVIEWS0004.
23. Nikoshkov A., Drakenberg K., Wang X., Horvath M.C., Keller E., Hurd Y.L. Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:786-791.
24. Nomura A., Ujike H., Tanaka Y., Otani K., Morita Y., Kishimoto M., Morio A., Harano M., Inada T., Yamada M., Komiyama T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci. Lett. 2006, 400:158-162.
25. Ray R., Doyle G.A., Crowley J.J., Buono R.J., Oslin D.W., Patkar A.A., Mannelli P., DeMaria P.A., O'Brien C.P., Berrettini W.H. A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatr. Genet. 2005, 15:295-298.
26. Rockman M.V., Hahn M.W., Soranzo N., Zimprich F., Goldstein D.B., Wray G.A. Ancient and recent positive selection transformed opioid cis-regulation in humans. PLoS Biol. 2005, 3:e387.
27. Schwarzer C. 30years of dynorphins - new insights on their functions in neuropsychiatric diseases. Pharmacol. Therapeut. 2009, 123:353-370.
28. Shippenberg T.S., Zapata A., Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacol. Therapeut. 2007, 116:306-321.
29. Spangler R., Unterwald E.M., Kreek M.J. 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Res. Mol. Brain Res. 1993, 19:323-327.
30. Thomas D.C., Witte J.S. Point: population stratification: a problem for case-control studies of candidate-gene associations?. Cancer Epidemiol. Biomarkers Prev. 2002, 11:505-512.
31. Tsuang M.T., Lyons M.J., Meyer J.M., Doyle T., Eisen S.A., Goldberg J., True W., Lin N., Toomey R., Eaves L. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch. Gen. Psychiatry 1998, 55:967-972.
32. Turchan J., Maj M., Przewlocka B., Przewlocki R. Effect of cocaine and amphetamine on biosynthesis of proenkephalin and prodynorphin in some regions of the rat limbic system. Pol. J. Pharmacol. 2002, 54:367-372.
33. van den Bree M.B., Johnson E.O., Neale M.C., Pickens R.W. Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug Alcohol Depend. 1998, 52:231-241.
34. Wang X.M., Zhou Y., Spangler R., Ho A., Han J.S., Kreek M.J. Acute intermittent morphine increases preprodynorphin and kappa opioid receptor mRNA levels in the rat brain. Brain Res. Mol. Brain Res. 1999, 66:184-187.
35. Xie X., Lu J., Kulbokas E.J., Golub T.R., Mootha V., Lindblad-Toh K., Lander E.S., Kellis M. Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 2005, 434:338-345.
36. Xuei X., Dick D., Flury-Wetherill L., Tian H.J., Agrawal A., Bierut L., Goate A., Bucholz K., Schuckit M., Nurnberger J., Tischfield J., Kuperman S., Porjesz B., Begleiter H., Foroud T., Edenberg H.J. Association of the kappa-opioid system with alcohol dependence. Mol. Psychiatry 2006, 11:1016-1024.
37. Yuferov V., Ji F., Nielsen D.A., Levran O., Ho A., Morgello S., Shi R., Ott J., Kreek M.J. A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology 2009, 34:1185-1197.
38. Zhang Y., Butelman E.R., Schlussman S.D., Ho A., Kreek M.J. Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl.) 2004, 172:422-429.
39. Zimprich A., Kraus J., Woltje M., Mayer P., Rauch E., Hollt V. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J. Neurochem. 2000, 74:472-477.